The effect on cartilage of different forms of application of postmenopausal estrogen therapy: Comparison of oral and transdermal therapy

Bone

Volumn 35, Issue 5, 2004, Pages 1216-1221

  Ravn, Pernille ^a   Warming, Lise ^a   Christgau, Stephan ^b   Christiansen, Claus ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

Cartilage degradation; CTX I; CTX II; Estradiol; Postmenopausal women

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL COLLAGEN TYPE II TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; DROSPERINONE; ESTRADIOL; ESTROGEN; LEVONORGESTREL; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METABOLISM; CARTILAGE DEGENERATION; CHONDROPROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; HIP; HORMONE DETERMINATION; HUMAN; NORMAL HUMAN; OSTEOLYSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SPINE;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; ALDOSTERONE ANTAGONISTS; ANDROSTENES; BONE DENSITY; CARTILAGE; COLLAGEN TYPE I; COLLAGEN TYPE II; DENMARK; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; PEPTIDE FRAGMENTS; TREATMENT OUTCOME;

EID: 8444233545     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.07.017     Document Type: Article

References (23)

1. M.J. Elders The increasing impact of arthritis on public health J. Rheumatol., Suppl. 60 2000 6 8
2. S. Boini, and F. Guillemin Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages Ann. Rheum. Dis. 60 2001 817 827
3. S. Christgau, P. Garnero, C. Fledelius, C. Moniz, M. Ensig, and E. Gineyts Collagen type II C-telopeptide fragments as an index of cartilage degradation Bone 29 2001 209 215
4. A. MacLennan, S. Lester, and V. Moore Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review Climacteric 4 2001 58 74
5. C. Christiansen, M.S. Christensen, and I. Transbøl Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy Lancet 1981 459 461
6. R. Rizzoli, and J.P. Bonjour Hormones and bones Lancet 349 1997 sI20-3
7. M.C. Nevitt, S.R. Cummings, N.E. Lane, M.C. Hochberg, J.C. Scott, and A.R. Pressman Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Study of Osteoporotic Fractures Research Group Arch. Intern. Med. 156 1996 2073 2080
8. E. Vingard, L. Alfredsson, and H. Malchau Lifestyle factors and hip arthrosis. A case referent study of body mass index, smoking and hormone therapy in 503 Swedish women Acta Orthop. Scand. 68 1997 216 220
9. D.T. Felson, and M.C. Nevitt The effects of estrogen on osteoarthritis Curr. Opin. Rheumatol. 10 1998 269 272
10. M.C. Nevitt, D.T. Felson, E.N. Williams, and D. Grady The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial Arthritis Rheum. 44 2001 811 818
11. U. Mouritzen, S. Christgau, H.J. Lehmann, L.B. Tankó, and C. Christiansen Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index Ann. Rheum. Dis. 62 2003 332 336
12. P. Høegh-Andersen, L.B. Tanko, T.L. Andersen, C.V. Lundberg, J.A. Mo, and A.M. Heegaard Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application Arthritis Res. Ther. 6 2004 R169 R180
13. S. Christgau, L.B. Tanko, P.A.C. Cloos, U. Mouritzen, C. Christiansen, and J.M. Delaisse Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen receptor modulator (SERM) Menopause 2004 [in press]
14. L. Warming, P. Ravn, T. Nielsen, and C. Christiansen Safety and efficacy of drosperinone used in a continuous combination with 17β-estradiol for the prevention of postmenopausal osteoporosis Climacteric 7 2004 1 9
15. L. Warming, P. Ravn, and C. Christiansen Levonorgestrel and 17β-estradiol given transdermally for the prevention of postmenopausal osteoporosis Maturitas 2004 [in press]
16. M. Bonde, P. Qvist, C. Fledelius, B.J. Riis, and C. Christiansen Immunoassay for quantifying type I collagen degradation products in urine evaluated Clin. Chem. 40 1994 2022 2025
17. C. Fledelius, A.H. Johnsen, P.A.C. Cloos, M. Bonde, and P. Qvist Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region J. Biol. Chem. 272 1997 9755 9763
18. P. Garnero, E. Gineyts, S. Christgau, B. Finck, and P.D. Delmas Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis Arthritis Rheum. 46 2002 21 30
19. P. Garnero, M. Piperno, E. Gineyts, S. Christgau, P.D. Delmas, and E. Vignon Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage Ann. Rheum. Dis. 60 2001 619 626
20. R.T. Turner, B.L. Riggs, and TC.. Spelsberg Skeletal effects of estrogen Endocr. Rev. 15 1994 275 300
21. P. Garnero, Y. Tsouderos, I. Marton, C. Pelissier, C. Varin, and P.D. Delmas Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women J. Clin. Endocrinol. Metab. 84 1999 2390 2397
22. N.B. Watts, J.C. Nolan, J.J. Brennan, and H.M. Yang Esterified estrogen therapy in postmenopausal women. Relationships of bone marker changes and plasma estradiol to BMD changes: a two-year study Menopause 7 2000 375 382
23. H.J. Lehman, U. Mouritzen, S. Christgau, P.A. Cloos, and C. Christiansen Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products Ann. Rheum. Dis. 61 2002 530 533